A Prediction Study of IL-18 and IFN-γ in Glucocorticoid Treatment Response in Infants and Young Children with Severe Pneumonia

Overview

Journal Transl Pediatr

Publisher AME Publishing Company

Specialty Pediatrics

Date 2022 Jun 10

PMID 35685073

Authors

Ruochen Zhu

Song Mao

Wenjing Shi

Liangxia Wu

Jianhua Zhang

Affiliations

Soon will be listed here.

Abstract

Background: In infants and young children, the clinical decision to apply glucocorticoids to severe pneumonia (SMPP) is more an empirical choice with reference to clinical symptoms, but the effect is not satisfying. We aimed to explore and identify early predictive indicators of ideal response to glucocorticoids treatment in SMPP in infants and young children.

Methods: We retrospectively reviewed the data of 59 patients, which met the age range and diagnostic criteria, admitted to Department of Pediatrics, the Sixth People's Hospital Affiliated to Shanghai Jiaotong University, from January to December 2017. Patients were divided into a glucocorticoid treatment group and a normal treatment group according to whether glucocorticoid treatment was used, and the difference in therapeutic effectiveness was compared between two groups. The glucocorticoid treatment group was further subdivided into effective versus ineffective treatment groups dependent on the difference of glucocorticoid treatment effect in main clinical symptoms improvement. We obtained the test value of biomarkers by ELISA, and identified several specific indicators with significantly different expressions in the early stage by independent sample -tests and calculated their cut-off values by ROC curve.

Results: Thirty-one SMPP patients who received glucocorticoid treatment were divided into effective and ineffective treatment groups according to the clinical improvements shown on different days of glucocorticoid use. The expression of two markers, interleukin-18 (IL-18) and interferon-γ (IFN-γ), were significantly different in cases showing improvement in the early stage of SMPP (P<0.05), and the cut-off values for IL-18 (218.19 pg/mL, AUC =0.581, sensitivity =0.909, 1-specificity =0.786) and IFN-γ (11.24 pg/mL, AUC =0.566, sensitivity =0.905, 1-specificity =0.795) were identified.

Conclusions: The expressions of IL-18 and IFN-γ in the early stage of SMPP might suggest their predictive effect of early application of glucocorticoid for effective treatment of SMPP in infants and young children. Further study with larger sample size will be carried on in the future.

Citing Articles

Predictive value of plasma sB7-H3 and YKL-40 in pediatric refractory Mycoplasma pneumoniae pneumonia.

Zhao Q, Ji S, Jiang H, Lu D, Qian L, Zhang J Open Med (Wars). 2025; 20(1):20241114.

PMID: 39822987 PMC: 11737367. DOI: 10.1515/med-2024-1114.

Construction and validation of a nomogram model to predict bronchiolitis Mycoplasma pneumoniae pneumonia in children.

Xiong S, Lin L, Chen Q, Peng J, Yang Y Sci Rep. 2024; 14(1):30758.

PMID: 39730508 PMC: 11681095. DOI: 10.1038/s41598-024-80906-0.

The role of LDH and ferritin levels as biomarkers for corticosteroid dosage in children with refractory Mycoplasma pneumoniae pneumonia.

Wei D, Zhao Y, Zhang T, Xu Y, Guo W Respir Res. 2024; 25(1):266.

PMID: 38965565 PMC: 11225272. DOI: 10.1186/s12931-024-02892-1.

The analysis of risk factors for recurrent wheezing in infants and clinical intervention.

Geng L, Tang X, Hua L, Liu H, Ren S, Zhong W Transl Pediatr. 2023; 12(10):1810-1822.

PMID: 37969130 PMC: 10644017. DOI: 10.21037/tp-23-45.

Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment.

Ihim S, Abubakar S, Zian Z, Sasaki T, Saffarioun M, Maleknia S Front Immunol. 2022; 13:919973.

PMID: 36032110 PMC: 9410767. DOI: 10.3389/fimmu.2022.919973.

References

Salvatore C, Fonseca-Aten M, Katz-Gaynor K, Gomez A, Mejias A, Somers C . Respiratory tract infection with Mycoplasma pneumoniae in interleukin-12 knockout mice results in improved bacterial clearance and reduced pulmonary inflammation. Infect Immun. 2006; 75(1):236-42. PMC: 1828434. DOI: 10.1128/IAI.01249-06. View

Narita M, Tanaka H . Late increase of interleukin-18 levels in blood during Mycoplasma pneumoniae pneumonia. Cytokine. 2012; 59(1):18-9. DOI: 10.1016/j.cyto.2012.04.007. View

Miyashita N, Obase Y, Ouchi K, Kawasaki K, Kawai Y, Kobashi Y . Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit. J Med Microbiol. 2007; 56(Pt 12):1625-1629. DOI: 10.1099/jmm.0.47119-0. View

Schultz M, Knapp S, Florquin S, Pater J, Takeda K, Akira S . Interleukin-18 impairs the pulmonary host response to Pseudomonas aeruginosa. Infect Immun. 2003; 71(4):1630-4. PMC: 152024. DOI: 10.1128/IAI.71.4.1630-1634.2003. View

Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M . British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011; 66 Suppl 2:ii1-23. DOI: 10.1136/thoraxjnl-2011-200598. View

Tamura A, Matsubara K, Tanaka T, Nigami H, Yura K, Fukaya T . Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Infect. 2008; 57(3):223-8. PMC: 7112643. DOI: 10.1016/j.jinf.2008.06.012. View

Ding S, Wang X, Chen W, Fang Y, Liu B, Liu Y . Decreased Interleukin-10 Responses in Children with Severe Mycoplasma pneumoniae Pneumonia. PLoS One. 2016; 11(1):e0146397. PMC: 4708986. DOI: 10.1371/journal.pone.0146397. View

de Benedictis F, Bush A . Corticosteroids in respiratory diseases in children. Am J Respir Crit Care Med. 2011; 185(1):12-23. DOI: 10.1164/rccm.201107-1174CI. View

Lu A, Wang C, Zhang X, Wang L, Qian L . Lactate Dehydrogenase as a Biomarker for Prediction of Refractory Mycoplasma pneumoniae Pneumonia in Children. Respir Care. 2015; 60(10):1469-75. DOI: 10.4187/respcare.03920. View

10.

Yu S, Xu L, Qi Q, Geng Y, Chen H, Meng Z . Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine-based chemotherapy. Sci Rep. 2017; 7:45194. PMC: 5366928. DOI: 10.1038/srep45194. View

11.

Narita M . Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special reference to pneumonia. J Infect Chemother. 2010; 16(3):162-9. DOI: 10.1007/s10156-010-0044-x. View

12.

Kurai D, Nakagaki K, Wada H, Saraya T, Kamiya S, Fujioka Y . Mycoplasma pneumoniae extract induces an IL-17-associated inflammatory reaction in murine lung: implication for mycoplasmal pneumonia. Inflammation. 2012; 36(2):285-93. DOI: 10.1007/s10753-012-9545-3. View

13.

Spuesens E, Fraaij P, Visser E, Hoogenboezem T, Hop W, Van Adrichem L . Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med. 2013; 10(5):e1001444. PMC: 3653782. DOI: 10.1371/journal.pmed.1001444. View

14.

Grossman J, Gordon R, Ranganath V, Deal C, Caplan L, Chen W . American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010; 62(11):1515-26. DOI: 10.1002/acr.20295. View

15.

Lauw F, Branger J, Florquin S, Speelman P, van Deventer S, Akira S . IL-18 improves the early antimicrobial host response to pneumococcal pneumonia. J Immunol. 2001; 168(1):372-8. DOI: 10.4049/jimmunol.168.1.372. View

16.

Miyashita N, Kawai Y, Inamura N, Tanaka T, Akaike H, Teranishi H . Setting a standard for the initiation of steroid therapy in refractory or severe Mycoplasma pneumoniae pneumonia in adolescents and adults. J Infect Chemother. 2014; 21(3):153-60. DOI: 10.1016/j.jiac.2014.10.008. View

17.

Xu Y, Zhu L, Xu D, Tao X, Li S, Tang L . Epidemiological characteristics and meteorological factors of childhood Mycoplasma pneumoniae pneumonia in Hangzhou. World J Pediatr. 2011; 7(3):240-4. DOI: 10.1007/s12519-011-0318-0. View

18.

Jacobs E . Mycoplasma pneumoniae: now in the focus of clinicians and epidemiologists. Euro Surveill. 2012; 17(6). View

19.

Kawamata R, Yokoyama K, Sato M, Goto M, Nozaki Y, Takagi T . Utility of serum ferritin and lactate dehydrogenase as surrogate markers for steroid therapy for Mycoplasma pneumoniae pneumonia. J Infect Chemother. 2015; 21(11):783-9. DOI: 10.1016/j.jiac.2015.07.009. View

20.

Weare-Regales N, Hudey S, Lockey R . Practical Guidance for Prevention and Management of Glucocorticoid-Induced Osteoporosis for the Allergist/Immunologist. J Allergy Clin Immunol Pract. 2021; 9(5):1841-1850. DOI: 10.1016/j.jaip.2020.12.050. View